Hyloris Pharmaceuticals SA (HYL.BR)

EUR 5.83

(0.34%)

Net Debt Summary of Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA's latest annual net debt in 2023 was -25.11 Million EUR , up 41.01% from previous year.
Hyloris Pharmaceuticals SA's latest quarterly net debt in 2023 FY was -25.11 Million EUR , up 41.01% from previous quarter.
Hyloris Pharmaceuticals SA reported annual net debt of -42.57 Million EUR in 2022, down -12.85% from previous year.
Hyloris Pharmaceuticals SA reported annual net debt of -37.72 Million EUR in 2021, up 32.58% from previous year.
Hyloris Pharmaceuticals SA reported quarterly net debt of -28.89 Million EUR for 2023 Q3, up 22.92% from previous quarter.
Hyloris Pharmaceuticals SA reported quarterly net debt of -37.68 Million EUR for 2023 Q1, up 11.49% from previous quarter.

Annual Net Debt Chart of Hyloris Pharmaceuticals SA (2023 - 2016)

Historical Annual Net Debt of Hyloris Pharmaceuticals SA (2023 - 2016)

Year	Net Debt	Net Debt Growth
2023	-25.11 Million EUR	41.01%
2022	-42.57 Million EUR	-12.85%
2021	-37.72 Million EUR	32.58%
2020	-55.95 Million EUR	-530.71%
2019	12.99 Million EUR	94.65%
2018	6.67 Million EUR	2.21%
2017	6.53 Million EUR	187.92%
2016	2.26 Million EUR	0.0%

Year	Net Debt	Net Debt Growth
2023 Q2	-37.48 Million EUR	0.52%
2023 Q3	-28.89 Million EUR	22.92%
2023 Q1	-37.68 Million EUR	11.49%
2023 FY	-25.11 Million EUR	41.01%
2023 Q4	-28.65 Million EUR	0.83%
2022 Q1	-50.82 Million EUR	-34.73%
2022 Q2	-57.62 Million EUR	-13.37%
2022 Q3	-32.71 Million EUR	43.23%
2022 FY	-42.57 Million EUR	-12.85%
2022 Q4	-42.57 Million EUR	-30.15%
2021 Q1	-45.16 Million EUR	19.35%
2021 FY	-37.72 Million EUR	32.58%
2021 Q4	-37.72 Million EUR	8.63%
2021 Q3	-41.28 Million EUR	22.59%
2021 Q2	-53.33 Million EUR	-18.09%
2020 Q4	-55.99 Million EUR	0.0%
2020 Q3	-55.99 Million EUR	4.08%
2020 Q1	15.62 Million EUR	20.68%
2020 FY	-55.95 Million EUR	-530.71%
2020 Q2	-58.37 Million EUR	-473.63%
2019 Q3	12.94 Million EUR	0.0%
2019 Q4	12.94 Million EUR	0.0%
2019 FY	12.99 Million EUR	94.65%
2019 Q1	2.68 Million EUR	0.0%
2018 FY	6.67 Million EUR	2.21%
2017 FY	6.53 Million EUR	187.92%
2016 FY	2.26 Million EUR	0.0%

Peer Net Debt Comparison of Hyloris Pharmaceuticals SA

Name	Net Debt	Net Debt Difference
Nicox S.A.	13.89 Million EUR	280.74%
European Medical Solutions	13.93 Million EUR	280.26%
FERMENTALG	4.19 Million EUR	698.903%
argenx SE	-1.83 Billion EUR	98.633%
BioSenic S.A.	28.04 Million EUR	189.545%
Celyad Oncology SA	-6.1 Million EUR	-311.537%
Onward Medical N.V.	-12.89 Million EUR	-94.757%
Oxurion NV	10.71 Million EUR	334.472%
PHAXIAM Therapeutics S.A.	-275 Thousand EUR	-9031.636%
Financière de Tubize SA	78.62 Million EUR	131.939%
UCB SA	2.17 Billion EUR	101.154%